Use of nonlinear mixed effects modelling in the development of in vitro-in vivo correlations

Advances in Experimental Medicine and Biology

Volumn 423, Issue , 1997, Pages 207-215

  Bigora, Sian ^a   Piscitelli, Deborah ^a   Dowell, James ^a   Butler, Jackie ^b   Farrell, Colm ^b   Devane, John ^b   Young, David ^a  

^a UNIVERSITY OF MARYLAND   (United States)

^b ELAN PHARMACEUTICALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CORRELATION FUNCTION; IN VITRO STUDY; IN VIVO STUDY; NONLINEAR SYSTEM; PHARMACEUTICS; PRIORITY JOURNAL; STATISTICAL MODEL;

DATA INTERPRETATION, STATISTICAL; DELAYED-ACTION PREPARATIONS; HUMANS; LINEAR MODELS; MODELS, BIOLOGICAL; MODELS, STATISTICAL; NONLINEAR DYNAMICS; PHARMACEUTICAL PREPARATIONS; PHARMACOKINETICS;

EID: 0030741348     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4684-6036-0_19     Document Type: Article

References (13)

1. Sheiner LB, Grasela TH. An introduction to mixed effects modeling: concepts, definitions and justification. J Pharmacokinetic Biopharm 1991;19:11S-23S.
2. Sheiner LB. The population approach to pharmacokinetic data analysis: rationale and standard data analysis methods. Drug Metab Rev 1984;15:153-71.
3. Sheiner LB, Beal SL. Evaluation of methods for estimating population pharmacokinetic parameters II. Biexponential model and experimental pharmacokinetic data. J Pharmacokinet Biopharm 1981;9:635-651.
4. Beal SL, Sheiner LB. Population pharmacokinetic data and parameter estimation based on their first two statistical moments. Drug Metab Rev 1984;15:173-93.
5. Beal SL and Sheiner LB. NONMEM Users guides, NONMEM Project Group, UCSF, San Francisco, CA, 1992.
6. In vitro-in vivo correlations. Pharmacopeial Forum USP 1993; 19:5374-9.
7. 'Draft guidance for industry: modified release solid dosage forms; scale-up and post-approval changes: chemistry, manufacturing and controls, in vitro dissolution testing and in vivo bioequivalence documentation. U.S. Department of Health and Human Services, Food and Drug Administration, July 1996.
8. Leeson LJ. In vitro/in vivo correlations. Drug Info J 1995;29:903-15.
9. Hussein Z, Freidman M. Release and absorption characteristics of novel theophylline sustained-release formulations: in vitro-in vivo correlation. Pharm Res 1990;7:1167-71.
10. Hyashi T, Ogura T, Takagishi Y. New evaluation method for in vitro/in vivo correlation of enteric coated multiple unit dosage forms. Pharm Res 1995;12:1333-7.
11. Gillespie WR, Veng-Pedersen P. A polyexponential deconvolution method. Evaluation of the "gastrointestinal bioavailability" and mean in vivo dissolution time of some ibuprofen dosage forms. J Pharmacokinet Biopharm 1985;13:289-307.
12. Gillespie WR. PCDCON: Deconvolution for pharmacokinetic applications. University of Texas at Austin, Austin TX. 1992
13. ADAPT II. D'Argenio D. Biomedical Simulations Resource, USC, CA.